Typically, when companies develop a drug, they must demonstrate its identity, as well as its purity, potency, and stability. But what those terms mean in the context of the microbiome, where the “drugs” may be communities of microbes, is still being defined. The methods so far available for identifying the microbial species within these complex communities yield highly variable results.
by Alla Katsnelson, special to C&EN |
July 14, 2019